1. Brown S, Traczewski M. Doripenem: in vitro potency, spectrum of activity, MIC and disc breakpoints. In: Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract E-2016, p. 175. American Society for Microbiology, Washington, DC, USA.
2. Traczewski MM, Brown SD. In vitro activity of doripenem versus 194 strains of P. aeruginosa and B. cepacia from both cystic fibrosis and non-cystic fibrosis patients. In: Abstracts of the One Hundred-fourth General Meeting of the American Society for Microbiology, New Orleans, LA, 2004. Abstract A-141, p. 28. American Society for Microbiology, Washington, DC, USA.
3. Tsuji M, Ishii Y, Ohno A et al. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother1998; 42: 94–9.
4. Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob Agents Chemother2004; 48: 1313–9.
5. Mikamo H, Izumi K, Hau YZ et al. In vivo and in vivo antibacterial activities of a new injectable carbapenem, S-4664, against gynaecological pathogens. J Antimicrob Chemother2000; 46: 471–4.